VEGF/VEGFR inhibitors 

Vascular endothelial growth factor (VEGF)/ vascular endothelial growth factor receptor (VEGFR) inhibitors are agents that inhibit the activity of VEGF and VEGFR. VEGR and VEGFR (a tyrosine kinase receptor) signaling modulates angiogenesis, which involves making of new blood vessels from existing blood vessels.

Abnormal angiogenesis is known to occur in cancer, degenerative eye conditions and other conditions that involve inflammation. Specific monoclonal antibodies can be used as VEGF inhibitors and particular tyrosine kinase inhibitors are used as VEGFR inhibitors.

Vascular endothelial growth factor (VEGF)/ vascular endothelial growth factor receptor (VEGFR) inhibitors are used to treat various types of cancers.

Anti-VEGF drugs (also called VEGF inhibitors) slow the abnormal growth of blood vessels associated with certain cancers and degenerative eye conditions, such as age-related macular degeneration. Anti-VEGF stands for anti-vascular endothelial growth factor.

Drugs that are known to interfere with the normal VEGF signaling pathway include bevacizumab, a monoclonal antibody; sorafenib and sunitinib, small molecule kinase inhibitors; and experimental drugs aflibercept, brivanib, cilengitide, axitinib, motesanib, and vandetanib.